Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265200 · ClinicalTrials.gov registry record · Phase 2
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
A Phase 2 study, sponsored by University of Louisville.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00265200 is a Phase 2 study that was terminated before completion, run by University of Louisville. The registered enrollment target is 28 participants.
The verdict
NCT00265200, a Phase 2 study, was terminated before completion, sponsored by University of Louisville.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.
Interventions
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2005-02 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265200
The ClinicalTrials.gov registry entry for NCT00265200 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which zoledronic acid is the first listed.
NCT00265200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265200 about?
NCT00265200 is a clinical study titled "Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer". The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.
What is the current status of trial NCT00265200?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2005-02. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00265200?
The interventions under investigation include: zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00265200?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.